Winship treats first lung cancer patient with T-cell receptor

As National Cancer Act turns 50, Winship Cancer Institute reflects on progress

Frontiers Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer

How Science Became Hope 50th Anniversary of the National Cancer Act

History of Winship Winship Cancer Institute

Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axis

Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

History of Winship Winship Cancer Institute

History of Winship Winship Cancer Institute

Landscape of HER2+ Metastatic Breast Cancer: Patient Overview

Going Public About Living with Inflammatory Bowel Disease

PDF) Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

PDF) JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer

Winship Magazine - Spring 2022 by EmoryWeb - Issuu